In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Abivax SA Sponsored ADR, with a price target of $116.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sam Slutsky’s rating is based on the promising results from Abivax’s Phase 2b trials, where obefazimod showed significant efficacy in a challenging patient population. The trial included patients who were highly refractory, with a substantial portion having been exposed to multiple lines of advanced therapies. The placebo-adjusted clinical remission rate for the most effective dose was notably high at 16.8%, which is impressive compared to other treatments in the market.
Slutsky also considers the competitive landscape, noting that a placebo-adjusted clinical remission rate of 10% or greater during induction would be favorable for the advanced therapy-experienced population. This positions obefazimod as a strong contender against existing therapies. Additionally, upcoming milestones, such as the Phase 3 maintenance study results expected in Q2 2026, further support the Buy rating, as they could potentially enhance the drug’s market position.
In another report released on September 25, Citizens JMP also maintained a Buy rating on the stock with a $114.00 price target.